<DOC>
	<DOCNO>NCT02263469</DOCNO>
	<brief_summary>The objective study assess safety efficacy Replenine®-VF child enrol study , age six year , severe haemophilia B .</brief_summary>
	<brief_title>A Study Investigate Safety Efficacy Replenine®-VF Haemophilia B Patients Under Age 6 Years</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Patients six year age time entry severe Haemophilia B time diagnosis without inhibitor FIX require Factor IX therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>